Hence, PSMA PET has a high diagnostic accuracy for the initial detection of PCa that makes it a reliable “rule out” test in patients with clinical and biochemical findings indicative of PCa, thus ensuring that unnecessary prostate biopsies are safely avoided. This evidence concerns the gene FOLH1 and posterior cortical atrophy.